3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Stomach Neoplasms
5
Pancreatic Neoplasms
4
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Rectal Neoplasms
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Locally Advanced Pancreatic Cancer
1
Liver Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoid Tumor
1
Breast Neoplasms
1
Biliary Carcinoma
1
Interventions
Fluorouracil
67
Radiotherapy
53
Cisplatin
52
Oxaliplatin
47
Leucovorin
37
Paclitaxel
36
Irinotecan
27
Docetaxel
23
Capecitabine
20
Nivolumab
17
Carboplatin
16
pembrolizumab
15
Radiation
15
Neoadjuvant Therapy
15
Surgical Procedures, Operative
12
Cetuximab
12
durvalumab
9
Drug Therapy
9
Biopsy
9
Taxes
8
Folfox protocol
8
Chemotherapy, Adjuvant
8
Trastuzumab
7
Magnetic Resonance Spectroscopy
7
Gefitinib
7
Endoscopy
7
tremelimumab
6
Specimen Handling
6
Endoscopy, Digestive System
6
Ramucirumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
zimberelimab
×
Gastrointestinal
×
Clear all
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled
NCT05568095
2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
1,040 enrolled